Clinical Trial Update: A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 long-term safety study of ND0612 delivered by continuous subcutaneous infusion in advanced Parkinson's disease has results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ND0612 (ND0612)

Snippet

Sponsor: NeuroDerm Ltd. | Conditions: Parkinson's Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-05-06